[an error occurred while processing this directive] | [an error occurred while processing this directive]
Analysis of failure patterns and survival after SBRT for 147 cases of T1-2N0M0 stage non-small cell lung cancer
Wang Lin1,2, Wang Ruiqi2, Dong Baiqiang3,4, Hu Xiao2, Ma Honglian2, Wang Zhun2, Lai Xiaojing2, Feng Wei2, Lin Xiao2, Jiang Youhua5, Wang Changchun5, Zhao Qiang5, Jiang Haitao6, Li Pu7, Du Xianghui2, Chen Ming3,4, Chen Qixun5, Xu Yujin2
1School of Medicine, Shaoxing University, Shaoxing 312000, China; 2Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China; 3State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; 4United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co., Ltd, Guangzhou 510060, China; 5Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China; 6Department of Radiology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China; 7Department of Radiation Physics, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China
AbstractObjective To analyze the failure patterns and survival after stereotactic body radiotherapy (SBRT) in patients with T1-2N0M0 non-small cell lung carcinoma (NSCLC). Methods Clinical data of early-stage NSCLC patients who received SBRT at Zhejiang Cancer Hospital from January 2012 to September 2018 were retrospectively analyzed. The primary observed endpoint was the pattern of disease progression, which was divided into intra-field recurrence, regional lymph node recurrence and distant metastasis. Overall survival (OS) and progression-free survival (PFS) were calculated by Kaplan-Meier method. Univariate analysis was conducted by log-rank test, and multivariate analysis was performed by Cox's model. Results A total of 147 patients with 156 lesions were included. The median follow-up time was 44.0 months (16.5-95.5 months). A total of 57 patients (38.8%) progressed: 14 patients (24.5%) had recurrence with the 1-, 3-, and 5-year local recurrence rates of 2.0%, 10.9%, and 14.3%, respectively; 36 patients (63.2%) had Distant metastasis with the 1-, 3- and 5-year distant metastasis rates of 12.2%, 22.4% and 28.6%, respectively; and 7 patients (12.3%) had recurrence complicated with distant metastasis. The 3-, 5- and 7-year OS rates were 80.5%, 64.2% and 49.9% for all patients, respectively. The median OS was 78.4 months. The 3-, 5- and 7-year PFS rates were 64.8%,49.5% and 41.5%, with a median PFS of 57.9 months (95%CI: 42.3-73.5 months). Univariate and multivariate analyses showed that biologically equivalent dose and age were the factors affecting the efficacy of SBRT (both P<0.05). Conclusion Distant metastasis is the main failure pattern in patients with T1-2N0M0 NSCLC after SBRT. High-risk population should be selected for further systematic treatment to improve the efficacy.
Fund:Medical and Health Research Project of Zhejiang Province (2020KY079); Beijing Xisike Clinical Oncology Research Foundation (Y-2019AZMS-0061); Beijing Science and Technology Innovation Medical Development Foundation (KC2021-JX-0186-63)
Wang Lin,Wang Ruiqi,Dong Baiqiang et al. Analysis of failure patterns and survival after SBRT for 147 cases of T1-2N0M0 stage non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2023, 32(8): 683-688.
Wang Lin,Wang Ruiqi,Dong Baiqiang et al. Analysis of failure patterns and survival after SBRT for 147 cases of T1-2N0M0 stage non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2023, 32(8): 683-688.
[1] Smythe WR.Treatment of stage I non-small cell lung carcinoma[J]. Chest, 2003,123(1 Suppl):181S-187S. [2] Timmerman R, Paulus R, Galvin J, et al.Stereotactic body radiation therapy for inoperable early stage lung cancer[J]. JAMA, 2010,303(11):1070-1076. DOI: 10.1001/jama.2010.261. [3] Peguret N, Dahele M, Lagerwaard F, et al.A brief report of 10-year trends in the use of stereotactic lung radiotherapy at a dutch academic medical center[J]. J Thorac Oncol, 2014,9(1):114-117. DOI: 10.1097/JTO.0000000000000012. [4] Iyengar P, Wardak Z, Gerber DE, et al.Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial[J]. JAMA Oncol, 2018,4(1):e173501. DOI: 10.1001/jamaoncol.2017.3501. [5] Morgensztern D, Du L, Waqar SN, et al.Adjuvant chemotherapy for patients with T2N0M0 NSCLC[J]. J Thorac Oncol, 2016,11(10):1729-1735. DOI: 10.1016/j.jtho.2016.05.022. [6] Paz-Ares L, O'Brien MER, Mauer M, et al. VP3-2022: pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 - PEARLS/KEYNOTE-091 study[J]. Ann Oncol,2022,33(4):451-453. DOI:10.1016/j.annonc.2022.02.224. [7] Baumann P, Nyman J, Hoyer M, et al.Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy[J]. J Clin Oncol, 2009,27(20):3290-3296. DOI: 10.1200/JCO.2008.21.5681. [8] Timmerman RD, Hu C, Michalski JM, et al.Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer[J]. JAMA Oncol, 2018,4(9):1287-1288. DOI: 10.1001/jamaoncol.2018.1258. [9] Azghadi S, Daly ME.Radiation and immunotherapy combinations in non-small cell lung cancer[J]. Cancer Treat Res Commun, 2021,26:100298. DOI: 10.1016/j.ctarc.2020.100298. [10] Bernstein MB, Krishnan S, Hodge JW, et al.Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?[J]. Nat Rev Clin Oncol, 2016,13(8):516-524. DOI: 10.1038/nrclinonc.2016.30. [11] Rodríguez-Ruiz ME, Vanpouille-Box C, Melero I, et al.Immunological mechanisms responsible for radiation- induced abscopal effect[J]. Trends Immunol, 2018,39(8):644-655. DOI: 10.1016/j.it.2018.06.001. [12] Timmerman RD, Paulus R, Pass HI, et al.Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG oncology RTOG 0618 trial[J]. JAMA Oncol, 2018,4(9):1263-1266. DOI: 10.1001/jamaoncol.2018.1251. [13] Onishi H, Araki T, Shirato H, et al.Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study[J]. Cancer, 2004,101(7):1623-1631. DOI: 10.1002/cncr.20539. [14] Kang J, Ning MS, Feng H, et al.Predicting 5-year progression and survival outcomes for early stage non-small cell lung cancer treated with stereotactic ablative radiation therapy: development and validation of robust prognostic nomograms[J]. Int J Radiat Oncol Biol Phys, 2020,106(1):90-99. DOI: 10.1016/j.ijrobp.2019.09.037.
2023, Vol. 32 
